Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBIT Margin: 2010-2024

Historic EBIT Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to 0.10%.

  • Ani Pharmaceuticals' EBIT Margin rose 2974.00% to 15.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.70%, marking a year-over-year increase of 660.00%. This contributed to the annual value of 0.10% for FY2024, which is 955.00% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EBIT Margin of 0.10% as of FY2024, which was down 99.01% from 9.65% recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' EBIT Margin registered a high of 9.65% during FY2023, and its lowest value of -18.41% during FY2021.
  • Over the past 3 years, Ani Pharmaceuticals' median EBIT Margin value was 0.10% (recorded in 2024), while the average stood at -0.47%.
  • In the last 5 years, Ani Pharmaceuticals' EBIT Margin plummeted by 1,560bps in 2020 and then surged by 2,080bps in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' EBIT Margin (Yearly) stood at -7.68% in 2020, then crashed by 1,073bps to -18.41% in 2021, then surged by 726bps to -11.15% in 2022, then skyrocketed by 2,080bps to 9.65% in 2023, then crashed by 955bps to 0.10% in 2024.